GlassScriptPhysician profile
Fady G Jamous
NPI 1912973785
$5,889.89
in general payments reported to CMS, 2019-2025
10 companies · $2,457 in 2025
The $2,457 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $49.91 · 2021: $29.79 · 2023: $21.58 · 2024: $3,177 · 2025: $2,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,378 · Education: $1,550 · Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,378.47 |
| Education | $1,549.86 |
| Food and Beverage | $726.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,461.11 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.43 | 2019 | |
| Jazz Pharmaceuticals INC. | $122.21 | 2025 | |
| Insmed, INC. | $66.10 | 2020-2025 | Brinsupri, Arikayce |
| Csl Behring | $63.46 | 2020-2021 | |
| Inspire Medical Systems, INC. | $21.58 | 2023 | Inspire |
| Sunovion Pharmaceuticals INC. | $13.30 | 2019 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Jamous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.